News - ALK Abello

Filter

Current filters:

ALK Abello

Popular Filters

ALK’s partner for Japan reports positive trial results for house dust mite SLIT-tablet

10-03-2014

Denmark-based allergy specialist ALK Abello said that its Japanese partner Torii Pharmaceutical has reported…

ALK AbelloDenmarkImmunologicalsJapanPharmaceuticalResearchTorii Pharma

ALK’s 2013 annual report shows profit down but sales steady

ALK’s 2013 annual report shows profit down but sales steady

05-02-2014

Denmark-based allergy specialist ALK Abello (ALKB: DC) has released its annual report for 2013 recording…

ALK AbelloDenmarkFinancialImmunologicalsPharmaceutical

ALK and Merck Co’s grass allergy tablet finally reaches FDA committee

ALK and Merck Co’s grass allergy tablet finally reaches FDA committee

10-12-2013

The US Food and Drug Administration Allergenic Products Advisory Committee will review US pharma giant…

ALK AbelloImmunologicalsMerck & CoPharmaceuticalRegulationUSA

Merck’s investigational Timothy grass allergy tablet reduced symptoms in Phase III study

Merck’s investigational Timothy grass allergy tablet reduced symptoms in Phase III study

12-11-2013

US pharma giant Merck & Co (NYSE: MRK) has published positive results for its investigational Timothy…

ALK AbelloGrazaxImmunologicalsMerck & CoNorth AmericaPharmaceuticalResearchUSA

ALK’s allergy tablet falls victim to US government shutdown

ALK’s allergy tablet falls victim to US government shutdown

08-10-2013

ALK Abello is the first pharma casualty of the US government shutdown.

ALK AbelloImmunologicalsMerk & CoNorth AmericaPharmaceuticalRegulation

ALK Abello loss narrows

14-08-2013

Denmark-based allergy specialist ALK Abello (ALKB: DC) revealed this morning (August 14) that revenues…

ALK AbelloFinancialPharmaceutical

Positive Ph III findings on ALK's new house dust mite allergy immunotherapy; EU filing expected in 2014

20-06-2013

Denmark-based allergy specialist ALK Abello (ALKB: DC) has announced positive outcome of the first of…

ALK AbelloImmunologicalsPharmaceuticalRegulationResearchRespiratory and Pulmonary

US FDA accepts Merck & Co's BLA for Timothy grass pollen allergy product

27-03-2013

US pharma giant Merck & Co (NYSE: MRK) says that its Biologics License Application for the investigational…

ALK AbelloGrazaxImmunologicalsMerck & CoPharmaceuticalRegulationRespiratory and Pulmonary

Merck & Co submits ragweed AIT BLA to the FDA

11-03-2013

US pharma giant Merck & Co (NYSE: MRK) has submitted a Biologics License Application (BLA) to the US…

ALK AbelloFinancialImmunologicalsMerck & CoNorth AmericaPharmaceuticalRegulation

ALK Abello partner Torii progresses Japanese development of Mitizax

01-08-2012

Denmark-based allergy specialist ALK Abello (ALKB: DC) revealed yesterday that its strategic partner,…

ALK AbelloImmunologicalsMitizaxPharmaceuticalResearchRespiratory and PulmonaryTorii Pharma

ALK-Abello expands in France and introduces new product

08-03-2012

Danish allergy immunotherapy specialist ALK-Abello (ALKB: DC) is to invests 18 million euros ($24.8 million)…

ALK AbelloEuropeFinancialMarkets & MarketingPharmaceuticalRespiratory and PulmonarySLIToneULTRA

FDA calls for more data on Merck combo drug; Good results with allergy drug

06-03-2012

The US Food and Drug Administration (FDA) has issued a Complete Response Letter to drug giant Merck &…

ALK AbelloatorvastatinCardio-vascularezetimibeImmunologicalsMerck & CoNorth AmericaPharmaceuticalRegulationResearch

UK NICE says yes to Lilly’s Bydureon and ALK-Abello’s Pharmalgen

22-02-2012

The UK’s health care guidance body the National Institute for Health and Clinical Excellence (NICE),…

ALK AbelloBydureonDiabetesEli LillyEuropePharmaceuticalPharmalgenPricingRegulationRespiratory and Pulmonary

Back to top